The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis
Research output: Contribution to journal › Article
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2018 Sep 5|
Related research output
Cellular and molecular mechanisms in immune mediated hepatic fibrosis. A study of the inflammatory syndrome and fibrosis development of the NIF mouse liver.Julia Nilsson, 2020, Lund : Lund University, Faculty of Medicine. 81 p.
Research output: Thesis › Doctoral Thesis (compilation)